Nigeria’s pharmaceutical manufacturers increased investment in factories, machinery and production facilities to N29.26bn in the first nine months of 2026, as companies step up efforts to expand local drug production and reduce dependence on imported medicines.
The five listed manufacturers, Fidson Healthcare, May & Baker Nigeria, MeCure Industries, Morrison Industries and Neimeth International Pharmaceuticals, recorded an 81% increase in capital expenditure from N16.20bn in the corresponding period of 2025. Their combined revenue also rose by 17.2% to N220.27bn from N187.98bn.
MeCure Industries accounted for the largest share of the investment, spending N16.69bn on capital projects, up 66% from N10.05bn a year earlier.
Fidson Healthcare followed with N9.97bn, while May & Baker increased its spending by 102% to N2.04bn. Neimeth recorded N541m, compared with N69m in the previous year.
The investment drive comes amid efforts to strengthen domestic pharmaceutical manufacturing.
The National Agency for Food and Drug Administration and Control (NAFDAC) introduced its 5+5 policy to encourage local production of medicines previously sourced from abroad.
As of May 2026, the agency reported that 20 new pharmaceutical facilities had been completed, while another 88 were under construction.
However, manufacturers still face challenges involving production costs, financing and access to imported raw materials.
The success of the expansion plans will depend on how quickly companies complete their projects, increase production and turn additional capacity into sustainable revenue.
Greater local manufacturing could also improve medicine availability and create opportunities for pharmaceutical exports across Africa.
Source: BusinessDay





